---
title: "默克與 Dr. Falk Pharma 簽署協議，獲得 MK-8690 的使用權，這是一種在研的抗 CD30 配體抗體"
description: "默克與 Dr. Falk Pharma 簽署協議，獲得 MK-8690 的權利，這是一種正在研究的抗 CD30 配體抗體"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/264214346.md"
published_at: "2025-11-04T12:05:47.000Z"
---

# 默克與 Dr. Falk Pharma 簽署協議，獲得 MK-8690 的使用權，這是一種在研的抗 CD30 配體抗體

> 默克與 Dr. Falk Pharma 簽署協議，獲得 MK-8690 的權利，這是一種正在研究的抗 CD30 配體抗體

### Related Stocks

- [MRK.US - 默克](https://longbridge.com/zh-HK/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Merck & Co. Insider Sold Shares Worth $1,827,992, According to a Recent SEC Filing | 04:30 PM EST, 02/06/2026 (MT Newswires) -- Johannes Jacobus Oosthuizen, President, US Market, on February 06, 2026, sold | [Link](https://longbridge.com/zh-HK/news/275175518.md) |
| Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says | [Link](https://longbridge.com/zh-HK/news/274841608.md) |
| Mankind Pharma says tax penalty of 4.6 million rupees dropped | Mankind Pharma says tax penalty of 4.6 million rupees dropped | [Link](https://longbridge.com/zh-HK/news/276062947.md) |
| Lupin Signs Licensing Pact with Spektus Pharma to Commercialize DeslaFlex in Canada | Lupin Signs Licensing Pact with Spektus Pharma to Commercialize DeslaFlex in Canada | [Link](https://longbridge.com/zh-HK/news/276114633.md) |
| NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.50 | NATCO Pharma Limited (NSE:NATCOPHARM) will pay a dividend of ₹1.50 per share on March 14, yielding 0.6%. Despite a forec | [Link](https://longbridge.com/zh-HK/news/275992839.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。